High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte MonolayersAndre Monteiro da Rocha 1, Andrew Allan 2, Travis Block 3, Jeffery Creech 1, Todd J. Herron 1
1Frankel Cardiovascular Regeneration Core Laboratory, Cardiovascular Medicine-Internal Medicine, University of Michigan, Ann Arbor, 2CAIRN Research, 3StemBioSys, Inc.
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer an alternative to using animals for preclinical cardiotoxicity screening. A limitation to the widespread adoption of hiPSC-CMs in preclinical toxicity screening is the immature, fetal-like phenotype of the cells. Presented here are protocols for robust and rapid maturation of hiPSC-CMs.
